Afficher la notice abrégée

High-risk human papillomavirus cervical infection prevalence: a nationwide retrospective study comparing opportunistic and organised screening, France, 2020 to 2023

dc.rights.licenseopenen_US
hal.structure.identifierCentre interdisciplinaire de recherche en biologie [CIRB]
dc.contributor.authorSUPPLISSON, Olivier
hal.structure.identifierMaladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle [MIVEGEC]
hal.structure.identifierCentre interdisciplinaire de recherche en biologie [CIRB]
dc.contributor.authorTESSANDIER, Nicolas
hal.structure.identifierLaboratoire CERBA [Saint Ouen l'Aumône]
dc.contributor.authorROUSSEL, Mathilde
hal.structure.identifierCerba HealthCare
dc.contributor.authorHAIM-BOUKOBZA, Stéphanie
hal.structure.identifierService de virologie et unité de surveillance biologique [Bordeaux]
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorBURREL, Sonia
hal.structure.identifierUniversité de Montpellier [UM]
hal.structure.identifierPathogenesis and Control of Chronic and Emerging Infections [PCCEI]
hal.structure.identifierCentre Hospitalier Universitaire de Nîmes [CHU Nîmes]
dc.contributor.authorSOFONEA, Mircea
hal.structure.identifierCentre interdisciplinaire de recherche en biologie [CIRB]
dc.contributor.authorALIZON, Samuel
dc.date.accessioned2025-09-01T08:11:58Z
dc.date.available2025-09-01T08:11:58Z
dc.date.issued2025-07-17
dc.identifier.issn1560-7917en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/207543
dc.description.abstractEnBACKGROUND In France, cervical cancer screening for females aged 30­–65 years primarily tests for high-risk (HR) human papillomavirus (HPV) infections. AIM We aimed to map the prevalence of cervical infections caused by HPV16 and/or 18, or by any of 12 other carcinogenic HPV genotypes and compare prevalence estimates from tests from spontaneous medical visits (opportunistic screening) or the national screening programme (organised screening). METHODS We extracted data from a large network of biology laboratories, containing all available results from HR HPV tests performed between 1 January 2020 and 30 November 2023 in metropolitan France. A full hierarchical Bayesian model was used to compute spatially resolved expected prevalence maps at the postcode level. RESULTS The analytic sample contained results of 362,963 HR HPV tests. Among samples positive for HPV16 and/or 18, 2.9% and 3.8% were from organised and opportunistic screening, respectively. Samples positive for other genotypes were 6.9% and 9.4%, respectively. During the last week of the study (week 48 2023), among females aged 30 years, opportunistic screening was associated with a greater expected prevalence of HPV16 and/or 18 and other genotypes in 97.2% and 99.9% of postcodes, respectively. The probability this percentage was lower among females aged 66 years was below 95% for both genotype groups. For organised screening, a pronounced north-west/south-east gradient in infection prevalence was found across France for both genotype groups, with hotspots located at the border with Italy, Spain and Switzerland.CONCLUSION Opportunistic screening is associated with systematic inflation of HR HPV infection prevalence.
dc.language.isoENen_US
dc.rights.urihttp://creativecommons.org/licenses/by/
dc.subject.enscreening
dc.subject.enspatial epidemiology
dc.subject.enmodel
dc.subject.enFrance
dc.subject.enHPV
dc.title.enHigh-risk human papillomavirus cervical infection prevalence: a nationwide retrospective study comparing opportunistic and organised screening, France, 2020 to 2023
dc.typeArticle de revueen_US
dc.identifier.doi10.2807/1560-7917.ES.2025.30.28.2400689en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologie/Virologieen_US
dc.subject.halStatistiques [stat]en_US
dc.identifier.pubmed40682451en_US
bordeaux.journalEurosurveillanceen_US
bordeaux.page2400689en_US
bordeaux.volume30en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.issue28en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-05191445
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Eurosurveillance&rft.date=2025-07-17&rft.volume=30&rft.issue=28&rft.spage=2400689&rft.epage=2400689&rft.eissn=1560-7917&rft.issn=1560-7917&rft.au=SUPPLISSON,%20Olivier&TESSANDIER,%20Nicolas&ROUSSEL,%20Mathilde&HAIM-BOUKOBZA,%20St%C3%A9phanie&BURREL,%20Sonia&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée